Interestingly, it has been demonstrated that the monoallelic deletion of PLCB1 gene correlates with adverse clinical outcomes and an increased risk of AML development both in high- and low-risk MDS patients [58]. Here, PLCB1 is linked to myelodysplastic syndrome.